Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 11;13(1):11.
doi: 10.1038/s41408-023-00785-y.

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

Utkarsh Goel  1 , Charalampos Charalampous  1 , Prashant Kapoor  1 , Moritz Binder  1 , Francis K Buadi  1 , David Dingli  1 , Angela Dispenzieri  1 , Amie Fonder  1 , Morie A Gertz  1 , Wilson I Gonsalves  1 , Suzanne R Hayman  1 , Miriam A Hobbs  1 , Yi L Hwa  1 , Taxiarchis Kourelis  1 , Martha Q Lacy  1 , Nelson Leung  1 , Yi Lin  1 , Rahma M Warsame  1 , Robert A Kyle  1 , S Vincent Rajkumar  1 , Shaji K Kumar  2
Affiliations

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

Utkarsh Goel et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

PK: Sanofi, BMS, Abbvie (Honoraria and Research Funding), Regeneron, Amgen, Ichnos, Loxo, Karyopharma, Takeda (Research Funding), Casma, Pharamcyclics, Imedex, GSK, Cellectar, Oncopeptides, X4 Pharmaceuticals (Honoraria). DD: Alexion, Apellis, BMS, Novartis, Roche, Sanofi (Consultancy), Regeneron (Research Funding). AD: Alynlam, Pfizer, Takeda, BMS (Research Funding), Janssen (Membership on an entity’s Board of Directors or advisory committees), Oncopeptides, Sorrento (Data monitoring safety committee). MAG: Ionis/Akcea, Prothena, Sanofi, Janssen, Aptitude Healthgrants, Ashfield, Juno, Physicians Education Resource, Johnson & Johnson, Celgene, Research to Practice, Sorrento (Personal Fees), Abbvie (Membership on an entity’s Board of Directors or advisory committees and Data monitoring safety committee), i3Health (Development of educational materials), TK: Novartis (Research Funding), MQL: Celgene (Research Funding), NL: Takeda (Membership on an entity’s Board of Directors or advisory committees), YL: Bluebird Bio, Celgene, Janssen, Kite (Consultancy and Research Funding), Gamida Cell, Novartis, Juno, Legend, Sorrento, Vineti (Consultancy), Merck, Takeda (Research Funding), Abbvie, Celgene, Janssen, Takeda, Adaptive, MedImmune/Astra Zeneca (Membership on an entity’s Board of Directors or advisory committees), Kite, Merck, Novartis, Roche, Sanofi (Research Funding), Oncopeptides (Independent review committee). The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Survival curves according to different classifications.
A Progression-free survival (PFS) by the number of prior lines of therapy. B Overall survival (OS) by the number of prior lines of therapy. C Progression-free survival (PFS) by refractoriness to the number of drug classes. D Overall survival (OS) by refractoriness to the number of drug classes.
See this image and copyright information in PMC

References

    1. Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015;126:921–2. doi: 10.1182/blood-2015-05-647636. - DOI - PubMed
    1. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–206. doi: 10.1016/S1470-2045(14)70440-1. - DOI - PubMed
    1. Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hájek R, et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017;31:115–22.. doi: 10.1038/leu.2016.186. - DOI - PMC - PubMed
    1. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38. doi: 10.1016/S1470-2045(15)00464-7. - DOI - PubMed
    1. Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, et al. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 2021;22:142–54. doi: 10.1016/S1470-2045(20)30680-X. - DOI - PubMed

MeSH terms